David Esposito

President and Chief Executive Officer

ONL Therapeutics

ONL Therapeutics is a biopharmaceutical company committed to protecting the vision of patients with a range of retinal diseases and conditions. 
 
ONL is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss and a leading cause of blindness.

Allergenis

AllerGenis is revolutionizing the diagnosis and management of food allergies with blood testing based on epitope-mapping technology.
AllerGenis was formed from a collaboration between Genisphere (proprietary amplification technology to increase the sensitivity of diagnostic tests) and Hugh Sampson, M.D., Director of the Jaffe Food Allergy Institute of the Mount Sinai School of Medicine.

Member of the Board of Directors

Hemotek

Hemotek is focused on bringing the benefits of Ox66 to multiple segments in the life science market.  Ox66 is the only solid form of oxygen, designed to be taken orally or applied topically, for its healing and pain relieving properties. Ox66 has the proven potential to provide oxygen to for any insult or injury to the human body resulting in low oxygen levels in cells and tissues.

Harvest Time Partners, Inc.

Harvest Time Partners, Inc. is a personal and professional development company.
We help YOU be your BEST for those you care about most - At Home - At Work - In Your Community
We create products and services to help YOU in the journey to reach your full potential.

Managing Partner

Shield Bio

Shield Bio has developed the Target-X platform, a solution to microbial detection, species identification and antibiotic susceptibility prediction with blazing speed and accuracy.
Shield Bio is building universal sequencing and has made 3rd Gen Sequencing work reliably and accurately in less than 1 minute

Evergreen Mergers & Acquisitions (EMA Partners, LLC)

EMA Partners supports middle market companies in evaluating and executing on key strategic initiatives including: (1) Business strategy transformation (2) Company sales, divestitures, and buy side acquisitions (3) Licensing and intellectual property monetization and (4) Capital raises and recapitalizations

Director

Medizone International (MZEI)

Director - Chairman Of The Board

Armune BioScience, Inc.

Armune BioScience developed and commercialized unique technology leveraging the immune system’s response to several types of cancers. Armune gained the interest of numerous strategic buyers and closed a deal with Exact Sciences in December of 2017 to acquire core assets of the business.

Chief Operating Officer

Thermo Fisher Scientific

Vice President, Commercial Operations US

Phadia AB

President, Phadia US

David is an experienced healthcare CEO and combat veteran.
He has built and scaled multiple healthcare companies that resulted in successful exits.
- CEO:  Armune BioScience (sold to Exact Sciences [EXAS] Dec. 2017).
- US President: Phadia US/AB (sold to Thermo Fisher Scientific [TMO] Sept. 2011)

Taplio

David Esposito's Linkedin Analytics

Want to drive more opportunities from LinkedIn?

Taplio

.css-1jgreyo{background-image:linear-gradient(284deg, rgba(39,43,72,1) 0%, rgba(33,47,183,1) 100%);color:transparent;-webkit-background-clip:text;background-clip:text;}David Esposito's Linkedin Analytics

Want to drive more opportunities from LinkedIn?

David Esposito's Linkedin Analytics